（文章来源：每日经济新闻） 每经AI快讯，10月30日，药明康德A股成交额达100亿元，现跌8.1%。 ...

药明康德A股成交额达100亿元，现跌8.1%。 ...

Core Viewpoint - The A-share market experienced a narrow fluctuation on October 30, 2023, with the steel sector showing significant gains, while several previously popular stocks faced adjustments [1][4][11]. Market Performance - The A-share market saw the Shanghai Composite Index fluctuating above 4000 points, with the North China 50 Index rising over 2% during the session, following a previous trading day where it surged by 8.41%, marking one of its best performances of the year [4]. - The steel sector was a highlight, with companies like Anyang Iron & Steel reaching the daily limit, and others such as Fangda Special Steel and New Steel Co. also showing strong gains [5]. Sector Analysis - The coal sector led the market with a rise exceeding 1.4%, driven by increasing prices of coking coal and coke, with coking coal futures rising over 3% and coke futures increasing by more than 2% [7]. - Other sectors such as electrical equipment, non-ferrous metals, transportation, and home appliances also showed notable gains [8]. - In contrast, sectors like telecommunications, comprehensive services, electronics, and building materials faced declines [9]. Conceptual Trends - Lithium mining concepts were among the top gainers, with the sector rising over 2%. Notable stocks included XWANDA, which surged by over 14%, and Dazhong Mining, which hit the daily limit [9][10]. - Other conceptual sectors like quantum technology, nickel metals, and remote work also performed well in the market [10].

Group 1 - The Hang Seng Index rose by 0.54%, gaining 141 points to close at 26,487 points, while the Hang Seng Tech Index increased by 0.31%. The morning trading volume in Hong Kong stocks reached HKD 178.7 billion [1] - Newly listed stock Dipu Technology (01384) surged by 36%, while Baima Tea (06890) rose over 8%, and Haixi New Drug (02637) increased by 7.59% [2] - The demand for energy storage driven by AI is expected to increase significantly, with CITIC Securities forecasting that total lithium battery demand will exceed 2,700 GWh next year, a year-on-year growth rate of over 30%. Energy storage battery demand is projected to exceed 900 GWh, leading to potential shortages in various lithium sectors [2] Group 2 - Ganfeng Lithium (01772) rose over 12%, and Tianqi Lithium (09696) increased by over 8% due to the strong performance of lithium mining stocks [2] - The energy storage sector saw significant gains, with Zhongchu Innovation (03931) rising over 12%, CATL (03750) increasing by 2.59%, and Shuangdeng Co. (06969) gaining over 7% [2] - Ruipu Lanjun (00666) increased by over 8% after the company launched several strategic new products covering energy storage, commercial vehicles, and passenger cars [3] Group 3 - Aneng Logistics (09956) surged by 22% following a privatization proposal from a major shareholder's consortium, with a premium rate exceeding 48% [4] - China Duty Free Group (01880) rose by 3% as the entire Hainan island is set to close in December, which is expected to boost the overall development of Hainan's tourism retail market [5] - China Hongqiao (01378) increased by nearly 7% due to recent production cuts in overseas electrolytic aluminum, which may further widen the supply-demand gap in the electrolytic aluminum market [6] Group 4 - Anjii Food (02648) rose over 8% with a 11.8% year-on-year growth in net profit attributable to shareholders in the third quarter, supported by a collaborative development across all channels [7] - The engineering machinery sector saw significant gains, with September exports continuing to grow year-on-year, and leading companies like Sany Heavy Industry (06031) rising by 9%, Senson International (02155) increasing by 8.02%, and China National Heavy Duty Truck Group (03808) gaining 3.7% [7] Group 5 - WuXi AppTec (02359) fell over 4% as the actual controller's shareholders plan to reduce their holdings by no more than 2% of the company's A-shares [8]

中银国际发表报告指，药明康德第三季业绩胜预期，延续上半年强劲势头，营收按年增长15%至121亿 元，净利润按年增长53%至约35亿元，主要得益于后期临床及商业化项目放量。毛利率按年提升7.8个 百分点至49.8%。报告指，撇除外汇影响，药明康德新增订单按年增长18%。在手订单规模达600亿元， 按年增长41%，预计在18个月内逐步转化，支撑2026年增长可见性。管理层将全年持续经营收入增速指 引上调至介乎17%至18%(原先介乎13%至17%)。该行上调2025至2027年盈利预测2.4至6.4%，H股目标 价从122港元上调至127港元，对应预测明年市盈率18倍不变，维持"买入"评级。 ...

每经AI快讯，药明康德(02359.HK)跌超6%，截至发稿，跌6.03%，报105.9港元，成交额6.52亿港元。 ...

智通财经APP获悉，药明康德(02359)跌超6%，截至发稿，跌6.03%，报105.9港元，成交额6.52亿港元。 消息面上，10月29日晚，药明康德公告，公司于2025年10月29日收到实际控制人控制的股东发出的《告 知函》。因自身资金需求，公司实际控制人控制的股东计划根据市场情况自本公告披露日起15个交易日 后的3个月内，通过集中竞价和/或大宗交易方式减持公司A股股份，减持股份数量不超过公司总股本的 2%，即合计不超过59675143股。 ...

Core Viewpoint - The main focus of the article is on the significant net inflow and outflow of capital in various sectors, highlighting the performance of specific companies and the overall market trends in different industries [1] Group 1: Capital Flow Analysis - Major capital inflow was observed in the energy metals, shipping ports, and textile sectors, indicating strong investor interest in these areas [1] - The electronic sector experienced a substantial net outflow exceeding 11.1 billion, suggesting a shift in investor sentiment away from this industry [1] Group 2: Company-Specific Movements - Huayou Cobalt saw a net capital inflow of over 500 million, ranking first among individual stocks, reflecting positive market sentiment towards the company [1] - New E-Sun faced a significant net sell-off exceeding 2.8 billion, indicating potential concerns among investors regarding its performance [1] - Other companies such as Zhongwei Company, Tianji Shares, and BlueFocus also received notable net inflows, while Tianfu Communication, WuXi AppTec, and Shenghong Technology experienced considerable net outflows [1]

Investment Rating - The report maintains a "BUY" rating for Pharmaron (3759.HK) since January 1, 2020, with a 12-month price target of HK$30.00, indicating an upside potential of 20.2% from the current price of HK$24.96 [1][12]. Core Insights - Pharmaron reported a 3Q25 revenue of Rmb3.65 billion, reflecting a year-over-year increase of 13.4% and a quarter-over-quarter increase of 9.1%, slightly exceeding Goldman Sachs estimates of Rmb3.48 billion. This growth was driven by strong performance in the CMC and bioscience segments, particularly from the top 20 large pharmaceutical clients [1][2]. - The management has raised the full-year revenue growth guidance to 12-16% year-over-year, up from the previous guidance of 10-15%, suggesting a potential growth of 6-20% year-over-year in 4Q25. The management is optimistic about further margin improvements in 4Q25 compared to the first nine months of 2025 [1][2]. - The report highlights robust new project order momentum, particularly in the CMC segment, where new project orders increased by 13% year-over-year for the first three quarters, with a notable 20% year-over-year rise in CMC new orders driven by large pharmaceutical demand [2][20]. Summary by Sections Earnings Review - 3Q25 revenue: Rmb3.65 billion, up 13.4% y/y and 9.1% q/q, slightly above GSe of Rmb3.48 billion [1]. - Non-IFRS adjusted net profit margin improved to 12.9%, up from 11.3% in 1Q25 and 12.2% in 2Q25, supported by higher utilization rates [1]. Revenue Growth and Guidance - Full-year revenue growth guidance raised to 12-16% y/y from 10-15% y/y, implying 4Q25 growth of 6-20% y/y [1]. - Continued investment in biologics and strategic acquisitions positions Pharmaron for sustained growth in the CDMO space [1][20]. Segment Performance - CMC revenue reached Rmb903 million, up 12.7% y/y and 29.6% q/q, with a gross margin of 34.6% [2]. - Clinical development revenue was Rmb501 million, up 8.2% y/y, but gross margin declined to 10.8% due to project mix and competitive pressures [3][19]. Strategic Acquisitions - The acquisition of Biortus is expected to enhance Pharmaron's biologics service offerings, particularly in structural biology data supporting drug discovery [20]. Financial Projections - Revenue projections for 2025E are Rmb14,066.7 million, with EBITDA of Rmb3,532.9 million and EPS of Rmb0.91 [6][17]. - The report anticipates a 3-year earnings CAGR of 15% [21].

每经AI快讯，10月30日，药明康德跌超6%，股东拟减持不超2%股份。 （文章来源：每日经济新闻） ...